Richard Davidson, Sarcoma UK Chief Executive
Friday, January 18, 2019

UPDATE 21 Jan 2019 We have been in contact with Eli Lilly and they want to assure patients that, as of now, olaratumab remains available for anyone already using it. You can of course discuss your options at your next visit to your clinician and the Support Line is, as always, available for anyone who would like to know more. We are preparing a more detailed comment which we will share next week online and on E-news.

------------------------------------------------------

Sarcoma UK is really disappointed to read the outcome of ANNOUNCE, a Phase 3 trial of the drug Lartruvo (also known as olaratumab) from the pharmaceutical company Lilly.

Eli Lilly and Company announced today that the results of the trial 'did not confirm the clinical benefit of Lartruvo in combination with doxorubicin', when treating advanced soft tissue sarcoma. You can read the full announcement from Lilly here.  

We are keeping abreast of the situation and will update you as soon as we know more about what this means for sarcoma patients. You can also stay up to date with developments about this through our Twitter feed (@Sarcoma_UK).

'Every step taken helps provide an answer. Soon we’ll get the answers we want.' Director of Research and Policy, Sarah McDonald, responds to the failure of Lartruvo.